{
  "patient_details": {
    "age": 65,
    "gender": "Male",
    "diagnosis": "Acute Myeloid Leukemia, s/p Stem Cell Transplant (Day +8)",
    "smoking_alcohol": "Not reported",
    "date_of_assessment": "2025-09-17"
  },
  "medication_assessments": [
    {
      "medication": "Paracetamol",
      "indication": [
        "Information not found in database"
      ],
      "benefits_specific_to_patient": "Information not found in database",
      "risks_and_interactions": "Information not found in database",
      "strength_of_evidence": "Information not found in database",
      "risk_minimisation_measures": [
        "Information not found in database"
      ],
      "fit_med_outcome": "Conditional",
      "recommendation": "Monitor for efficacy and adverse effects. Consider alternative if no response."
    },
    {
      "medication": "Thyroxine USPI",
      "indication": [
        "Hypothyroidism",
        "Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression"
      ],
      "benefits_specific_to_patient": "Replacement therapy for hypothyroidism, adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.",
      "risks_and_interactions": "Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease, myxedema coma, acute adrenal crisis in patients with concomitant adrenal insufficiency, prevention of hyperthyroidism or incomplete treatment of hypothyroidism, worsening of diabetic control, decreased bone mineral density associated with thyroid hormone over-replacement, drug interactions affecting thyroid hormone pharmacokinetics and metabolism.",
      "strength_of_evidence": "Available prescribing information",
      "risk_minimisation_measures": [
        "Monitor TSH and/or Thyroxine (T4) levels",
        "Assess for cardiac adverse reactions, especially in elderly patients",
        "Monitor for drug interactions"
      ],
      "fit_med_outcome": "Conditional",
      "recommendation": "Monitor TSH and T4 levels regularly. Assess for potential drug interactions and cardiac adverse reactions, especially given the patient's age. Ensure adequate absorption and compliance."
    },
    {
      "medication": "Sitagliptin USPI",
      "indication": [
        "Treatment of diabetes"
      ],
      "benefits_specific_to_patient": "May help manage blood sugar levels.",
      "risks_and_interactions": "Potential adverse reactions, although sitagliptin has a low propensity for clinically meaningful drug-drug interactions mediated by plasma protein binding displacement.",
      "strength_of_evidence": "Available prescribing information",
      "risk_minimisation_measures": [
        "Monitor for adverse reactions",
        "Consider potential drug interactions"
      ],
      "fit_med_outcome": "Conditional",
      "recommendation": "Monitor for adverse reactions and drug interactions. Assess blood glucose levels regularly."
    }
  ],
  "monitoring_protocol": [
    {
      "medication": "Thyroxine USPI",
      "monitoring_parameters": [
        "TSH levels",
        "Thyroxine (T4) levels",
        "Cardiac function"
      ],
      "frequency": "Regularly, as clinically indicated"
    },
    {
      "medication": "Sitagliptin USPI",
      "monitoring_parameters": [
        "Blood glucose levels",
        "Adverse reactions"
      ],
      "frequency": "Regularly, as clinically indicated"
    }
  ],
  "summary": [
    {
      "medication": "Paracetamol",
      "recommendation": "Monitor for efficacy and adverse effects."
    },
    {
      "medication": "Thyroxine USPI",
      "recommendation": "Monitor TSH and T4 levels, assess for drug interactions and cardiac adverse reactions."
    },
    {
      "medication": "Sitagliptin USPI",
      "recommendation": "Monitor blood glucose levels and adverse reactions."
    }
  ]
}